Research note · June 2026
Midjourney, Inc. is an independent research lab that originally built its massive profitability in text-to-image artificial intelligence generation. Founded in 2021 by David Holz, the company has operated as a significant anomaly in the generative AI ecosystem by scaling entirely through a bootstrapped, self-sustaining financial framework.
In a major strategic expansion unveiled in June 2026, Midjourney has extended its research and product development into medical hardware with the launch of the “Midjourney Scanner.” This device is a low-cost, safe, full-angle water-immersion soft tissue scanner designed to enable frequent, longitudinal whole-body structural baselines. While it faces technical limitations inherent to ultrasound-style imaging—such as an inability to penetrate bone, see through air-filled lungs, or image past the skull—it represents an aggressive move into medical multiomics and metabolic health tracking.
Company Overview & Hardware Expansion
- Revenue & Profitability: Midjourney generates hundreds of millions in annual recurring revenue (ARR) while operating at significant profit margins. It achieved profitability within its first six months of operation.
- Operational Efficiency: The company services tens of millions of users with a remarkably lean head count, achieving an industry-leading revenue-per-employee metric.
- Infrastructure Model: Compute expenses are treated as a variable cost by leasing cloud infrastructure, allowing the company to fund both its AI models and its new medical hardware R&D entirely out of organic cash flow.
Strategic Shift: The Midjourney Scanner
The company’s expansion into medical imaging has fundamentally altered its long-term valuation thesis, shifting it from a pure software application play into a hardware-enabled biological data ecosystem. Prominent longevity investor Bryan Johnson heavily highlighted the disruptive potential of this technology following its mid-June 2026 unveiling:
“The Midjourney scanner is revolutionary. There’s a bullish case that exceeds the most optimistic takes… Most of the early commentary has focused on the wrong questions: ‘is it as good as MRI?’ and ‘what about false positives?’ These are legitimate concerns, but they miss the bigger shift. The more important question is: what does fast, low cost, safe whole body imaging unlock? … Midjourney can help flip harm-by-default into a new expectation for our health infrastructure: almost no one will ever again be blindsided by a late-stage, life-threatening diagnosis that could have been caught earlier reasonably and cost-effectively.” — Bryan Johnson (@bryan_johnson), June 23, 2026
According to early technical disclosures, the scanner excels at mapping soft tissue structures, positioning it to track critical indicators like visceral fat, muscle fat infiltration, liver fat (metabolic health), and endocrine tissues. The long-term commercial unlock relies on repeated, low-friction measurement to establish structural trajectories rather than single-point diagnostic crises.
Share Structure and Absolute Nontradability
Despite the heightened investor interest surrounding the scanner’s launch, Midjourney remains completely locked to outside capital. Institutional and private equity investors must recognize the following absolute barriers to executing transactions:
- Absence of Venture-Backed Float: Because the company has never executed a primary institutional funding round, there are no early-stage venture capital firms or growth equity funds holding blocks of shares to liquidate on secondary markets.
- Inaccessibility of Employee Equity: Midjourney does not maintain a standard, liquid employee stock option pool (ESOP). The company rewards its lean team through top-tier cash compensation and direct profit-sharing from its massive operational cash flows.
- Restrictive Corporate Governance: The company’s cap table is tightly controlled and entirely private. Shares are subject to ironclad transfer restrictions and strict Corporate Rights of First Refusal (ROFR). Midjourney has no debt pressures and no stated intention to pursue an Initial Public Offering (IPO).
There is currently no viable, direct legal path to acquire or trade equity in Midjourney, Inc. Any secondary indications of interest or synthetic structures offered on private desks are structurally unfillable.